A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

"Their effects on vaginal health are an important consideration that is often overlooked," gynecologist Melanie Bone told ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Ultimately, the right stocks for your portfolio will depend on numerous factors, including your risk tolerance level, ...

Like many health plans, Lilla’s insurance didn’t cover Wegovy for weight loss use. Out of pocket, a month’s supply came with a price tag of more than $1,300. Even after applying a coupon from the drug ...

实际上，2024年是多肽类药物火热的一年，司美格鲁肽、利拉鲁肽、替尔泊肽等重磅胰高血糖素样肽1（下称“GLP-1”）药物成为全球备受关注的“减肥神药”，且凭借着一己之力催生出了庞大的原料药市场。

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...